CD274 and neoplasm: Among the various therapeutic strategies, immune checkpoint inhibitors (ICIs), particularly those targeting the programmed death ligand‐1 (PD‐L1) and programed cell death‐1 (PD‐1) pathway, have shown great promise in activating the body's immune system to combat tumor growth [2, 3].